Phaseline

Targets › HTR1B

HTR1B (5-hydroxytryptamine receptor 1B): drug programs, companies and trials

6 programs from 4 companies in 8 trials: 6 Phase 1, 2 Phase 2; Other, Neurology, Psychiatry; next expected readout Dec 2026.

G protein-coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). (UniProt, P28222)

Open in Phaseline: the race on HTR1B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University Hospital, Basel, SwitzerlandLysergic Acid Diethylamide Tartrate (LSD)
Serotonin receptor agonist (5-HT1B/1D/7)
HTR1B, HTR1DPhase 2Palliative Care; Cluster HeadacheSep 2027
Yale UniversityDimethyltryptamine (DMT)
Serotonin 5-HT receptor agonist; endogenous psychedelic compound
HTR1A, HTR1B, HTR1D, HTR2APhase 1Major Depressive Disorder; Alcohol Use Disorder (AUD)Dec 2026
TechnophageEletriptan Hydrobromide
Serotonin 1f (5-HT1f) receptor agonist; Serotonin 1b (5-HT1b) receptor agonist; Serotonin 1d (5-HT1d) receptor agonist
HTR1F, HTR1B, HTR1DPhase 1Acute Spinal Cord Injury (SCI)Dec 2026
Leukos BiotechLB-208
HTR1B antagonist
HTR1BPhase 1Solid Tumor MalignanciesDec 2026
University Hospital, Basel, SwitzerlandDMT
5-HT receptor agonist, primarily 5-HT1A and 5-HT7
HTR1A, HTR1B, HTR1D, HTR5A, HTR7Phase 1Healthy–
University Hospital, Basel, SwitzerlandLSD
5-HT receptor agonist, primarily 5-HT1A and 5-HT7
HTR1A, HTR1B, HTR1D, HTR5A, HTR7Phase 1Healthy–

Conditions

Healthy (2) Palliative Care (1) Cluster Headache (1) Major Depressive Disorder (1) Alcohol Use Disorder (AUD) (1) Solid Tumor Malignancies (1) Acute Spinal Cord Injury (SCI) (1)

Modalities

small molecule (6)

Companies

University Hospital, Basel, Switzerland (3) Yale University (1) Leukos Biotech (1) Technophage (1)

Related targets

HTR1D (5) HTR1A (3) HTR5A (2) HTR7 (2) HTR2A (1) HTR1F (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.